Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
- New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
- Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
- GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
- Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Research & Development
- Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
- Biomarkers found that could be drug targets against a deadly form of brain cancer
- COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
- Novel drug combo activates natural killer cell immunity to destroy cancer cells
- Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
- A new technology offers treatment for HIV infection through a single injection
- Proteomic study of 2,002 tumors identifies 11 pan-cancer molecular subtypes across 14 types of cancer
Conferences & Events
- New approach to treatment of deadly kidney cancer
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
- FDA approves first generic of Symbicort to treat asthma and COPD